Behind The Knife: The Surgery Podcast

Journal Review in Surgical Oncology: Gastric Cancer

Oct 22, 2026
Joseph Broderick, a surgical oncology research resident, and Daniel Nelson, a surgical oncologist specializing in multidisciplinary cancer care, examine the MATTERHORN trial in resectable gastric and gastroesophageal junction cancer. They trace the evolution from MAGIC to FLOT4, explore durvalumab’s role with perioperative FLOT, and discuss survival, nodal response, safety, biomarkers, and unresolved surgical questions.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

MAGIC Made Perioperative Therapy Standard

  • MAGIC established perioperative chemotherapy as superior to surgery alone for resectable gastric and gastroesophageal cancer.
  • Neoadjuvant therapy improved five-year survival from 23% to 36% and enabled about 90% of patients to complete planned treatment.
INSIGHT

FLOT Became The Gastric Cancer Backbone

  • FLOT replaced ECF or ECX as the preferred perioperative chemotherapy backbone after improving survival, R0 resection, and pathological response.
  • The episode notes that FLOT remains intensive, with fewer than half of patients completing every allocated cycle.
INSIGHT

Why Durvalumab Joins FLOT

  • Durvalumab blocks PD-L1 checkpoint signaling, restoring T-cell recognition of cancer; chemotherapy may simultaneously release tumor antigens.
  • In non-MSI-high gastric cancer, immunotherapy supplements rather than replaces FLOT, so added benefit must justify additional toxicity.
Get the Snipd Podcast app to discover more snips from this episode
Get the app